Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Featured Clinical Trials Supported by the National Cancer Institute

Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.

To find other cancer trials open to enrollment:

  • Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
  • Use the clinical trials search form to look online for trials listed on NCI's website. The form has a Help link for tips about searching for clinical trials.
  • For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
  • Optimizing Chemotherapy with Bevacizumab for Ovarian Cancer
    (Posted: 02/09/2010) - In this trial, patients with stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cancer will be randomly assigned to receive one of three regimens using intravenous or intravenous and intraperitoneal chemotherapy in addition to bevacizumab.
  • Adjuvant Bevacizumab and Chemotherapy for High-risk Breast Cancer
    (Posted: 01/26/2010) - In this trial, patients with lymph node-positive or high-risk, lymph node-negative breast cancer who have received radiation therapy or plan to do so following chemotherapy will be treated with adjuvant chemotherapy and randomly assigned to receive short-term treatment with bevacizumab, long-term treatment with bevacizumab, or an intravenous placebo.
  • PARP Inhibitor and Metronomic Chemotherapy for Refractory Cancer
    (Posted: 01/12/2010) - In this clinical trial, patients with solid tumors or lymphomas that have not responded to previous treatment (refractory cancer), or for which no effective treatment exists, will receive the PARP inhibitor ABT-888 and metronomic cyclophosphamide.
  • Targeted Therapy for Ovarian Cancer
    (Posted: 10/31/2006, Updated: 01/06/2010) - In this trial, women who have undergone initial surgery for ovarian cancer or primary peritoneal cancer will receive standard intravenous chemotherapy and some will receive additional treatment with bevacizumab.
  • Defining Optimal Therapy for Metastatic and Recurrent Cervical Cancer
    (Posted: 12/15/2009) - In this phase III trial, women with metastatic, recurrent, or persistent cervical cancer that cannot be treated with surgery and/or radiation therapy will be randomly assigned to one of four treatment groups: paclitaxel plus cisplatin, paclitaxel plus topotecan, or either of these combinations with the addition of bevacizumab.
< Previous  6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26  Next >